Flamma Group

Flamma Group, established in 1950, is a significant player in the Pharmaceuticals and Healthcare sectors, operating six locations across Europe. The company provides a comprehensive suite of pharmaceutical services, including current Good Manufacturing Practice (cGMP) manufacturing for Active Pharmaceutical Ingredients (APIs), Raw Starting Materials (RSMs), and New Chemical Entities (NCEs). Their capabilities also encompass robust process research and development (R&D), ensuring high-quality output and technical proficiency for clients requiring specialized chemical synthesis and manufacturing solutions. Flamma Group is dedicated to delivering dependable assessments of technical packages and formulating competitive, viable offers for complex pharmaceutical development projects.

The company's product offerings include a diverse range of compounds, specialty chemicals, APIs, and generic formulations such as minoxidil and melatonin, catering to niche markets with specific value propositions. Flamma Group offers custom development services, meticulously tailored to meet unique client requirements. Supported by a dedicated team of 500 - 1,000 employees, the company harnesses extensive internal expertise to drive innovation and maintain operational excellence in its specialized field. Meet Flamma Group's team to learn more about the professionals powering these advanced services.

With a reported revenue of $257.2M, Flamma Group demonstrates substantial market presence and operational scale within the pharmaceutical services industry. Their commitment to quality and scientific rigor underpins their ability to provide advanced solutions, from early-stage process R&D to commercial-scale cGMP manufacturing. The company's strategic focus on specialized chemical synthesis and API development positions it as a key partner for pharmaceutical and biotechnology firms seeking reliable and high-caliber manufacturing support.